In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs Greg Scott joined Foley's Eye on China webinar on life science innovation >>Foley webinar...
|
Simcere’s Q4 Revenues Climb, but Earnings Are Down
publication date: Mar 12, 2009
Simcere Pharmaceutical Group (先声药业), which makes both branded generic pharmaceuticals and the anti-angiogenesis cancer drug Endu, reported Q4 revenues climbed 17% to 467 million RMB ($68.4 million), but net income fell 34% to 52 million RMB ($7.6 million). Simcere did not attribute the net income shortfall to any particular cause. Although expenses were higher in all categories, most of the increases in each category were more or less in line with the rise in revenues. The only dramatic increase was in R&D spending, which was up 114% to 34.0 million RMB ($5.0 million). Stock symbol: (NYSE: SCR)
|
Partner Events
BioPharm America™ 2010Boston, MA, USA September 15–17, 2010 CALAsia 2010San Diego, USA October 4-5, 2010 CHINA PRETRIALS 2010: Global Preclinical Development Summit Beijing, China October 17-19, 2010 CHINA TRIALS 2010 Beijing, China November 7-9, 2010 12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM) Beijing, China November 9-11, 2010
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|